Sex and Gender Reporting and Female Participation Relative to Disease Burden in ClinicalTrials.gov
In the authors' words
Importance: Assessing representation by sex assigned at birth and gender identity requires reporting of both in trials. If disclosure of full gender and sex participation from clinicaltrials.gov is limited, it poses challenges in characterization and understanding of those participant experiences. Objective: To determine how often ClinicalTrials.gov trials published trials report sex and gender, which characteristics are associated with reporting, and how participants' female share compares with that of the general public. Design, Setting, and Participants: Cross-sectional study of interventional trials registered to ClinicalTrials.gov, with or without US sites, with primary completion on or after September 27, 2008, and results first posted from January 1, 2009, through April 30, 2026. Exposures: Funder type, phase, US sites, enrollment, primary completion year, number of countries, and therapeutic area. Main Outcomes and Measures: Reporting of sex and gender, and the female participation-to-prevalence ratio (PPR; trial female share divided by the number of people with the condition). Results: Among 58,007 trials (median enrollment, 72 [IQR, 31 to 206]; 42,644 [74%] with US sites), 553 (0.95%) reported gender and 57,683 (99.44%) reported sex. Gender reporting was more common with National Institutes of Health (NIH) funding (odds ratio [OR], 9.05; 95% CI, 6.65 to 12.6), US sites (OR, 4.21; 95% CI, 2.96 to 6.22), and larger enrollment. Across 10 conditions (15,552 mixed-sex trials), median PPR ranged from 0.68 (95% CI, 0.64 to 0.71) for chronic obstructive pulmonary disease to 1.05 (95% CI, 1.01 to 1.09) for obesity and had a relatively lower female share in 8. Among the 10 conditions most prevalent in our cohort, 6,917 of 16,097 trial condition combinations (43.0%) reached a PPR of at least 0.90; odds of reaching it were higher for NIH-funded (OR, 1.22; 95% CI, 1.11 to 1.34) and lower for government-funded trials (OR, 0.26; 95% CI, 0.20 to 0.33) as compared to industry-funded trials. Conclusions and Relevance: In ClinicalTrials.gov, sex reporting is nearly universal, whereas gender reporting is concentrated among NIH-funded, US-based, and larger trials. Female trial enrollment fell below the female share of people with the condition for most conditions, emphasizing the benefit of condition-specific benchmarks in clinical trials.
Appeared: Wednesday, November 18. medRxiv. Preprint, not yet peer-reviewed.